citing AstraZeneca's ongoing capital expenditures including its $300 million investment announced on Tuesday in a facility in Maryland for discovery and development of cell therapies. "There is a ...

By leveraging our cutting-edge discovery capabilities and AstraZeneca's expertise in drug ... The company is building its robust portfolio and differentiated pipeline through internal R&D ...

The consortium's goal is to build the largest enterprise AI supercomputer in Sweden, once it becomes operational.

Bloomberg reported on May 23 that Nvidia Corp. (NASDAQ:NVDA) is partnering with a group of Swedish companies, including ...

A Swedish business consortium including AstraZeneca, Saab and Ericsson unveiled a pact with Nvidia to build local AI ...

The first thing Promise Bio CEO Ronel Veksler wants you to know about the biotech company he co-founded is that it’s not another AI drug discovery company. Instead, he’s looking to bring ...

This is the latest in a string of tie-ups by Anglo-Swedish drugmaker AstraZeneca to use artificial intelligence for drug discovery and development, including a $247 million deal with U.S.-based ...

is possible given AstraZeneca's position as one of the leading pharmaceutical companies on artificial intelligence integration in drug discovery and data science. Currently, AZN shares are trading ...